Merck Stock Plummets 36.58% Year-To-Date Amid Revenue Growth
Merck & Co.'s stock has taken a significant hit, plummeting by 36.58% year-to-date as of September 15, 2026. This decline makes it the clearest signal for investors to consider.
The company's stock price closed at $143.76 on the NYSE that day, down 0.17% from its prior close of $144.00. It remains below its yearly high, which was $156.92.
Despite revenue growth of 4.6% to $66.57 billion in trailing-twelve-month data, net income took a sharp dive of 80.7% to $3.17 billion. Earnings per share also declined by 80.4%. The valuation picture is mixed, with a trailing price-to-earnings ratio of 115.06 and a forward ratio of 17.32.
The next earnings date for Merck & Co. is October 29, 2026, giving investors a checkpoint to assess the gap between current earnings and forward valuation.